Amneal Pharmaceuticals, Inc. - News - Press Releases

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Jul 10, 2020

Amneal Launches Generic Fluphenazine Following ANDA Approval by FDA

Jul 08, 2020

Amneal to Report Second Quarter 2020 Results on August 6, 2020

Jun 03, 2020

Amneal Pharmaceuticals LLC Issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended Release Tablets, USP, 500 mg and 750 mg, due to Detection of N-Nitrosodimethylamine (NDMA) Impurity to Consumer Level

May 11, 2020

Amneal Reports First Quarter 2020 Financial Results

Apr 24, 2020

Amneal to Report First Quarter 2020 Results on May 11, 2020

Apr 16, 2020

Amneal Launches Generic Butrans® Following ANDA Approval by FDA

Apr 15, 2020

Amneal Pharmaceuticals Moving to a Virtual Meeting Format for 2020 Annual Meeting of Stockholders

Apr 15, 2020

Amneal Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Nizatidine Oral Solution, 15 mg/mL, Due to Potential Levels of N-nitrosodimethylamine (NDMA) Impurity amounts above the levels established by FDA

Mar 26, 2020

State of Texas and Senator Bryan Hughes Secure a Donation of Hydroxychloroquine Sulfate from Amneal Pharmaceuticals for Texas Patients

Mar 20, 2020

Amneal Accelerates Distribution and Production of Hydroxychloroquine Sulfate to Meet Potential Needs of COVID-19 Patients Nationwide

Mar 11, 2020

Amneal Pharmaceuticals Appoints Tasos Konidaris as Senior Vice President, Chief Financial Officer

Feb 26, 2020

Amneal Reports Fourth Quarter and Full Year 2019 Financial Results

Jan 24, 2020

Amneal to Report Fourth Quarter and Full Year 2019 Results on February 26, 2020

© Amneal Pharmaceuticals LLC.

All rights reserved.

Powered By Q4 Inc. 5.37.0.2